These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 9786361)
41. Advice for users on compliance with Devices Act. Patterson P OR Manager; 1991 May; 7(5):1, 14-5. PubMed ID: 10110590 [No Abstract] [Full Text] [Related]
42. The learned intermediary doctrine: past, present and future. Alsobrook HB Leg Med; 1994; ():269-80. PubMed ID: 7830482 [No Abstract] [Full Text] [Related]
43. Medication risk must be balanced with benefit, not fear. Jones KW Ann Pharmacother; 2010 Apr; 44(4):737-9. PubMed ID: 20332340 [TBL] [Abstract][Full Text] [Related]
44. How is a food product recalled? Cunningham E J Am Diet Assoc; 2009 Aug; 109(8):1488. PubMed ID: 19631055 [No Abstract] [Full Text] [Related]
45. Patient package inserts: the proper prescription? Rowe HM Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988 [No Abstract] [Full Text] [Related]
46. Class labeling: FDA concepts and approach. Lewis BP Am Pharm; 1980 Feb; NS20(2):40-2. PubMed ID: 7355710 [No Abstract] [Full Text] [Related]
47. The drug safety review process. Somberg J Am J Ther; 2007; 14(2):119. PubMed ID: 17414577 [No Abstract] [Full Text] [Related]
48. MedWatch. FDA's 'heads up' on medical product safety. Henkel J FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445 [No Abstract] [Full Text] [Related]
49. FDA needs more sophisticated approach to drug safety. Christie B BMJ; 2005 May; 330(7501):1166. PubMed ID: 15905236 [No Abstract] [Full Text] [Related]
50. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Berry MD Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449 [No Abstract] [Full Text] [Related]
51. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care. Watson KT; Barash PG Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852 [TBL] [Abstract][Full Text] [Related]
52. Contributing to drug safety. Johnson JM Am J Hosp Pharm; 1990 Jun; 47(6):1280. PubMed ID: 2368721 [No Abstract] [Full Text] [Related]
53. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine. Fern FH; Bartell L Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381 [TBL] [Abstract][Full Text] [Related]
55. US lawmakers tackle safety reforms at the FDA. Zwillich T Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942 [No Abstract] [Full Text] [Related]
56. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule. Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687 [TBL] [Abstract][Full Text] [Related]
57. An interview with FDA commissioner Hayes. Small WE Am Pharm; 1981 Oct; NS21(10):27-36. PubMed ID: 6803557 [No Abstract] [Full Text] [Related]
58. Drug safety: a contrarian's point of view. Cobert B Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392 [No Abstract] [Full Text] [Related]
59. Over-the-counter product line extensions: have we reached the limit yet? Sansgiry SS J Am Geriatr Soc; 2004 Jul; 52(7):1223-4. PubMed ID: 15209675 [No Abstract] [Full Text] [Related]
60. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. Qato DM; Alexander GC JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]